Learn More
OBJECTIVE Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological(More)
OBJECTIVE To assess the analgesic efficacy and safety of 5 mg of oxymorphone immediate release (IR) for mild to moderate pain. DESIGN Multicenter, double-blind, randomized, placebo-controlled(More)
  • 1